Busulfan pharmacokinetic parameters are useful in predicting the outcome of allogeneic bone marrow transplantation (BMT). Standard pharmacokinetic measurements require multiple blood samples. Various limited sampling models (LSM) have been proposed for reducing the sample number required for these measurements, essentially for patients with malignant disorders undergoing BMT. This study was undertaken to evaluate the existing LSM for busulfan pharmacokinetics to find out the most suitable method for patients with thalassaemia major undergoing BMT. Busulfan levels in plasma samples were analysed by HPLC. The AUC calculated by non-compartmental analysis using the program 'TOPFIT' was compared with previously published LSMs. Our seven sample pharmacokinetic data for AUC calculation was compared with the pub- 15 A high incidence of hepatic toxicities related to conditioning therapy has been reported. 16 We have also shown that there is a correlation between busulfan pharmacokinetics and rejection in these patients. 17 Evaluation of busulfan pharmacokinetics therefore acquires particular significance in these patients.
has shown that several factors including age of the patient, [4] [5] [6] underlying disease, 7, 8 chronopharmacology, 9, 10 food 11 and concomitant administration of other drugs 12 affect the pharmacokinetics of oral busulfan. It has also been demonstrated that both in adult and pediatric patients, dose adjustment according to pharmacokinetic parameters could improve the outcome of allogeneic BMT by reducing regimen-related toxicities and relapse of disease. 13, 14 Most patients with thalassaemia major undergoing BMT have abnormal liver functions due to iron overload and hepatitis virus infections. 15 A high incidence of hepatic toxicities related to conditioning therapy has been reported. 16 We have also shown that there is a correlation between busulfan pharmacokinetics and rejection in these patients. 17 Evaluation of busulfan pharmacokinetics therefore acquires particular significance in these patients.
The conventional seven to 12 sample (per dose) model is accurate for analysis of busulfan kinetics but requires frequent blood sampling, which is inconvenient for the patient, nursing and laboratory staff, and increases the cost of evaluation. Various studies have proposed limited sampling models (LSM) for determination of AUC based on two to three samples per dose of busulfan. These LSM approaches provided data comparable to those of conventional sampling procedures but without the disadvantages of the latter. However, such correlations have essentially been assessed in patients with malignant disorders undergoing BMT. So far, LSMs have not been evaluated in children with non-malignant inherited disorders. The purpose of this study was to explore whether a LSM was applicable to patients with thalassaemia major undergoing BMT. To this end, we have compared the busulfan AUC (calculated by TOPFIT) obtained from conventional multisampling procedure to that obtained by LSM procedures in order to establish the most suitable method for patients with thalassaemia major.
Patients and methods

Patients
Patients with beta thalassaemia major undergoing BMT were assigned to one of the two conditioning regimens as 
Pharmacokinetic analysis
Busulfan in plasma samples was analysed by HPLC as previously described. 19 AUC was calculated by non-compartmental analysis using the computerized program TOPFIT (version 2.0). 20 
Limited sampling models
The AUC in the published LSM are calculated by using a combination of the trapezoidal rule, which is used to calculate AUC from time 0 to a particular dosing interval (eg 0-6 h) and the logarithmic rule, which derives the extrapolated AUC up to infinity using the formula Cx/Ke, where Cx = plasma concentration at time x after the dose and Ke is the elimination rate constant. These formulae were arrived at by stepwise multiple linear regression with the AUC as dependent and the individual concentrations as independent variables. Busulfan AUC calculated by TOP-FIT was compared with AUCs calculated using the following LSMs:
(1) Chattergoon et al: where C 0.5h , C 1h , C 1.5h , C 2h , C 4h and C 6h represents the busulfan plasma concentrations after 0.5, 1, 1.5, 2, 4 and 6 h, respectively, of busulfan dose; Ln represents the natural logarithm. Chattergoon's and Vassal's models were proposed for children and estimate AUC 0-inf whereas Schuler's model was proposed for adults and estimates AUC 0-6 h.
Statistical analysis
Linear regression analysis was applied to compare the AUCs calculated by TOPFIT vs AUC calculated by various LSMs, using SPSS version 7.5 for Windows.
Results and discussion
The estimated AUC values derived from different LSM protocols were compared with AUC values obtained from conventional measurement of all samples using TOPFIT 20 (Table 1) . When analyzed by linear regression analysis, a significant agreement (R 2 = 0.79-0.98) was found between all these models except with the model proposed by Vassal et al 22 (R 2 = 0.61, Table 1 ). The mean difference in the calculated AUC for each of these models from the observed values was less than 5% for all except the two sample model of Chattergoon et al 21 and the model proposed by Vassal et al 22 where it was lower by 5.29% and 6.38%, respectively. Figure 1 describes the linear regression of AUCs calculated by all the proposed LSMs vs TOPFIT. Figure 2 shows the ratio plots of AUCs estimated by these models and those determined by TOPFIT.
The best correlation was found between AUC TOPFIT and the three sample LSM of Chattergoon et al 21 (R 2 = 0.98). Although all other models except the one proposed by Vassal et al 22 correlated significantly, the mean difference was much lower with this model (2.35%, range 1.6-5.5%). AUC (0-6 h) calculated by Schuler's 11 three sample LSM also showed a good agreement (R 2 = 0.94) with AUC (0-6 h) TOPFIT, with a mean difference of 1.38% (range 0.6-2.5%), although this model was proposed for adults. However, Hassan et al 23 have reported that this model of Schuler et al's 11 resulted in a mean underestimation of 25% (range 2-50%) in the calculation of AUC in children and that the differences were more pronounced at higher AUCs. It was their conclusion that Schuler's model was proposed for AUC calculation in adults and it therefore cannot be used to estimate AUC in children. A similar discrepancy was observed by Chattergoon et al 21 when compared with Schuler's LSM. Schuler's AUC calculations were based on AUC 0-6 h at first dose, whereas Chattergoon and Hassan calculated AUC 0-inf. It is remarkable that our data from children with thalassaemia major correlated well with Schuler's three sample LSM in adults. The reason for this is not clear but suggests that the cause of discordance noted by Hassan and Chattergoon may not be the age difference of the subjects studied. Schuler's two sample model showed a less significant agreement with AUC (0-6 h) TOPFIT than the three sample model (R 2 = 0.79).
Vassal's 22 LSM was proposed for children in the age range of 1.92 to 13.83 years. When we applied it for calculating AUC for our patient group, we noted significant differences when compared to the AUC obtained by conventional multisample procedure using TOPFIT, with a mean difference of 6.4% (range 1-26%). This discrepancy may be attributed to variation in T max observed in the present study (0.5-6 h). The median T max in the present study was 1. their models, 21, 23 none of the authors reported significant correlation between the models. The correlation of determined AUC observed in the present study with other models could be due to the use of the non-compartmental model for AUC calculation in this study, as opposed to the one compartment models used by Hassan 22 and Chattergoon.
21
In conclusion, we have identified Chattergoon's 21 (using 1 h, 1.5 h and 6 h samples) and Schuler's (using 1, 2 and 4 h samples) three sample models to be the most suitable for AUC calculation in children with thalassaemia major for busulfan dose adjustment. These data can now be used to apply LSM for assessment of busulfan pharmacokinetics in patients with thalassaemia major undergoing BMT and thus contribute to cost reduction, and convenience in sample analysis and above all patient's comfort.
